Article3 Biotech2021
Ethosomes-based gel formulation of karanjin for treatment of acne vulgaris: in vitro investigations and preclinical assessment.
Article in 3 Biotech, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Ultra-deformable transethosomal vesicle for enhancing transdermal delivery of NSAIDs: a comprehensive review.Inflammopharmacology · 2026Review
- Ethosomal nanocarriers for enhanced skin drug delivery: a comprehensive review.Molecular biology reports · 2026Review
- A Quality-by-Design Approach Based Formulation, Optimization, In Vitro and Ex Vivo Evaluation of Delafloxacin-Loaded Ethosomal Gel.AAPS PharmSciTech · 2026Article
- Lipid-Based Nanocarriers as a Promising Delivery System in the Management of Acne.Current pharmaceutical design · 2026Review
- Selective Modulation ofClinical, cosmetic and investigational dermatology · 2026Review
- QbD Optimized Nanoemulsion Based Topical Formulation of Jatyadi Taila: Unveiling its In Vitro and In Vivo Efficacy for Enhanced Wound Healing.Pharmaceutical research · 2025Article
- Article
- Modified Phospholipid Vesicular Gel for Transdermal Drug Delivery: The Influence of Glycerin and/or Ethanol on Their Lipid Bilayer Fluidity and Penetration Characteristics.Gels (Basel, Switzerland) · 2025Review
- Development and Characterization of a Hydrogel Containing Chloramphenicol-Loaded Binary Ethosomes for Effective Transdermal Permeation and Treatment Acne in Rat Model.International journal of nanomedicine · 2025Article
- Plant-Based Nanovesicular Gel Formulations Applied to Skin for Ameliorating the Anti-Inflammatory Efficiency.Gels (Basel, Switzerland) · 2024Review
- Lawsone Unleashed: A Comprehensive Review on Chemistry, Biosynthesis, and Therapeutic Potentials.Drug design, development and therapy · 2024Review
- New Insights in Topical Drug Delivery for Skin Disorders: From a Nanotechnological Perspective.ACS omega · 2023Review
- Ethosomal gel for rectal transmucosal delivery of domperidone: design of experiment,Drug delivery · 2022Article
- Topical Administration of Drugs Incorporated in Carriers Containing Phospholipid Soft Vesicles for the Treatment of Skin Medical Conditions.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to develop and characterize karanjin-loaded ethosomes-based gel formulation for enhanced topical delivery and effective therapy of skin acne. Karanjin-loaded ethosomes (K-ETH) presented a nanometric size of 140.87 ± 2.35 nm, entrapment of 71.41 ± 2.74% and enhanced permeation with 1.9 times increase in the flux and 2.4 times higher skin deposition compared to the hydro-ethanolic solution of karanjin. The DSC analysis confirmed successful entrapment of the karanjin within the ethosomes. The developed ethosomes were incorporated in the carbopol gel for adequate application on the skin surface. The ethosomal gel (K-EGF) also exhibited greater penetration in the rat skin as revealed by CLSM. The optimized K-EGF formulation was non-irritant to the skin as evident by Draize score test and histopathological examination. The highest zone of inhibition, 30.0 ± 1.52 mm and 36.22 ± 0.57 mm was produced by the K-EGF against SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13205-021-02978-3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.